Enbo Zhu

Sep 23, 2024 | nature.com | Enbo Zhu |Jiaji Yu |Yan-Ruide Li |Feiyang Ma |Yang Liu |James Brown | +2 more

AbstractChimeric antigen receptor (CAR)-engineered T cells represent a front-line therapy for cancers. However, the current CAR T cell manufacturing protocols do not adequately reproduce immunological synapse formation. Here, in response to this limitation, we have developed a flexible graphene oxide antigen-presenting platform (GO-APP) that anchors antibodies onto graphene oxide.